ARQT - Arcutis starts enrollment in mid-stage vitiligo treatment study

Arcutis Biotherapeutics (ARQT) announces enrollment of the first patient in a Phase 2a clinical trial evaluating ARQ-252 as a potential treatment for vitiligo, an auto-immune condition characterized by the loss of natural skin color or discolored patches on various parts of the body. ARQ-252 is a potent and highly selective topical small molecule inhibitor of Janus kinase type 1 ((JAK1)).This Phase 2a study is a parallel group, double blind, vehicle-controlled study of the safety and efficacy of ARQ-252 0.3% cream either with or without narrowband UVB (NB-UVB) phototherapy treatment in about 500 subjects with non-segmental facial vitiligo. Topline data expected in the second half 2023.The primary endpoint of the study is the proportion of subjects achieving Facial Vitiligo Area Scoring Index-75 (F-VASI-75), which is ? 75% improvement from baseline in F-VASI at week 24.Arcutis is also developing ARQ-252 0.3% cream as a potential treatment for chronic hand eczema and expects to report topline data from a

For further details see:

Arcutis starts enrollment in mid-stage vitiligo treatment study